The Significance of COVID-19 Immunological Status in Severe Neurological Complications and Multiple Sclerosis-A Literature Review.
Joanna KulikowskaAgnieszka Kulczyńska-PrzybikBarbara MroczkoAlina KułakowskaPublished in: International journal of molecular sciences (2021)
SARS-CoV-2/Coronavirus 2019 (COVID-19) is responsible for the pandemic, which started in December 2019. In addition to the typical respiratory symptoms, this virus also causes other severe complications, including neurological ones. In diagnostics, serological and polymerase chain reaction tests are useful not only in detecting past infections but can also predict the response to vaccination. It is now believed that an immune mechanism rather than direct viral neuroinvasion is responsible for neurological symptoms. For this reason, it is important to assess the presence of antibodies not only in the serum but also in the cerebrospinal fluid (CSF), especially in the case of neuro-COVID. A particular group of patients are people with multiple sclerosis (MS) whose disease-modifying drugs weaken the immune system and lead to an unpredictable serological response to SARS-CoV-2 infection. Based on available data, the article summarizes the current serological information concerning COVID-19 in CSF in patients with severe neurological complications and in those with MS.
Keyphrases
- sars cov
- multiple sclerosis
- respiratory syndrome coronavirus
- coronavirus disease
- cerebrospinal fluid
- early onset
- mass spectrometry
- risk factors
- white matter
- ms ms
- end stage renal disease
- ejection fraction
- newly diagnosed
- physical activity
- cerebral ischemia
- prognostic factors
- patient reported outcomes
- healthcare
- depressive symptoms
- sleep quality
- case report